This chart is a good example. The SOC drugs have response rates of only 20% and 37% (source is the Oct 23 announcement). And this response rate is as a 1st line of treatment, and was sufficient for an FDA approval. CHM's drug has shown a 55% response rate, and longer median survival rates.
I hope this better explains why CHM is confident re accelerated approval. Replication of the previous results already shows improvement over the already FDA approved drugs.
Hopefully with the Phase 1B ttial happening as a 2 line of treatment, further improvement will be seen in response rates and survival. But this is still an unknown.
